Salim Dhanji
Directeur Général chez ME THERAPEUTICS HOLDINGS INC.
Fortune : 20 M $ au 30/04/2024
Profil
Salim Zulifkar Dhanji is currently the Chief Executive Officer & Executive Director at ME Therapeutics Holdings, Inc. since 2023 and the President at Perceptive Property Development since 2013.
He previously worked as the Director-Preclinical Research at Qu Biologics, Inc. from 2009 to 2014.
Dr. Dhanji received his undergraduate degree in 2001 and his doctorate in 2006 from the University of British Columbia.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/02/2024 | 4 175 143 ( 17,72% ) | 20 M $ | 30/04/2024 |
Postes actifs de Salim Dhanji
| Sociétés | Poste | Début |
|---|---|---|
| ME THERAPEUTICS HOLDINGS INC. | Directeur Général | 09/03/2023 |
Anciens postes connus de Salim Dhanji
| Sociétés | Poste | Fin |
|---|---|---|
Qu Biologics, Inc.
 Qu Biologics, Inc. BiotechnologyHealth Technology Qu Biologics, Inc. develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer. The firm specializes in ulcerative colitis, Crohn's disease, arthritis, cancer, autoimmune diseases, autoimmune disorders, inflammatory bowel disease, IBD, Site Specific Immunomodulators, immunotherapies, investigational drug, auto-immune, pharmaceuticals, research, inflammation, biotech and clinical trials. The company was founded by Harold David Gunn and Rob Freeman in 2007 and is headquartered in Burnaby, Canada. | Corporate Officer/Principal | 01/01/2014 |
Formation de Salim Dhanji
| University of British Columbia | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ME THERAPEUTICS HOLDINGS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Qu Biologics, Inc.
Qu Biologics, Inc. BiotechnologyHealth Technology Qu Biologics, Inc. develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer. The firm specializes in ulcerative colitis, Crohn's disease, arthritis, cancer, autoimmune diseases, autoimmune disorders, inflammatory bowel disease, IBD, Site Specific Immunomodulators, immunotherapies, investigational drug, auto-immune, pharmaceuticals, research, inflammation, biotech and clinical trials. The company was founded by Harold David Gunn and Rob Freeman in 2007 and is headquartered in Burnaby, Canada. | Health Technology |